Common Interactions with Metformin
Januvia (sitagliptin) is frequently combined with metformin, the first-line diabetes drug. No significant pharmacokinetic interactions occur; they are approved together in fixed-dose combinations like Janumet. Clinical trials show additive blood sugar lowering without increased hypoglycemia risk when used at standard doses.[1][2]
Interactions with Sulfonylureas (e.g., Glipizide, Glyburide)
Sitagliptin boosts insulin release from sulfonylureas, raising hypoglycemia risk. Dose adjustments for sulfonylureas are often needed. Studies report 1.5-2 times higher hypoglycemia incidence in combination therapy versus monotherapy.[1][3]
Effects with Insulin
Combining Januvia with insulin enhances glycemic control but elevates hypoglycemia odds. The TECOS trial found no excess cardiovascular risk, though monitoring blood glucose closely is advised during initiation.[2][4]
Use with SGLT2 Inhibitors (e.g., Empagliflozin, Canagliflozin)
No major interactions; combinations improve A1C by 0.5-1% more than either alone. Hypoglycemia risk stays low since SGLT2s work independently of insulin secretion.[1][5]
Interactions with GLP-1 Agonists (e.g., Liraglutide, Semaglutide)
Generally safe, with complementary DPP-4 inhibition and GLP-1 mimicry. Some trials note minor GI side effect overlap, but no pharmacokinetic clashes. Dual incretin therapy is common in type 2 diabetes.[2][6]
Risks with Digoxin and Other Drugs
Januvia slightly increases digoxin levels (by 11%), so monitor digoxin in heart patients. No notable interactions with statins, ACE inhibitors, or thiazides, but cyclosporine can raise sitagliptin exposure—dose reduction may be required.[1][3]
Overall Hypoglycemia and Monitoring
Januvia alone rarely causes low blood sugar, but pairing with insulin secretagogues or insulin demands caution. FDA labels recommend starting low and titrating. Renal impairment worsens risks for all combinations.[2]
[1]: Januvia Prescribing Information (Merck)
[2]: Drugs.com - Januvia Interactions
[3]: Medscape - Sitagliptin Drug Interactions
[4]: TECOS Trial (NEJM, 2015)
[5]: ADA Standards of Care 2023
[6]: UpToDate - DPP-4 Inhibitors